AfroCentric Investment Corp

AfroCentric Investment Corp

ACT · JSE · Healthcare / Medical Care Facilities

71.00ZAC+1.00 (+1.43%)

Price History

Full chart

Market Stats

Previous Close70.00
Open70.00
Day Range70.00 – 71.00
52-Week Range56.00 – 165.00
Volume14.11K
Market Cap605.94M
P/E (TTM)0.00
Forward P/E8.37
EPS-0.81
Dividend Yield0.00%
Beta0.21
50-Day Avg74.96
200-Day Avg94.70

About

AfroCentric Investment Corporation Limited, an investment holding company, provides healthcare products and services to private and public sectors in South Africa and internationally. The company operates through Healthcare SA, Healthcare Retail, Healthcare Africa, and Information Technology segments. It offers health administration, health risk management, medical scheme administration, marketing and distribution, as well as specialized and technology-based products and services; HIV/AIDS management; DBC equipment and administration services to musculoskeletal treatment centres; and dental management services. The company also engages in the manufacture, distribution, marketing, and retail of medicines and pharmaceutical products under the Pharmacy Direct, Curasana, Activo Health, and Scriptpharm brand names. In addition, it provides health insurance products for individuals and organisations; occupational health programmes; administration services for a market of medical schemes, health insurers and corporate clients; wellness programmes, including health risk assessments, corporate nursing, lifestyle initiatives, executive wellness, and employee assistance programmes; chronic condition monitoring, referrals, health education and emergency services; and gap cover, a short-term insurance product that offers additional financial protection to medical aid members. The company was incorporated in 1988 and is based in Roodepoort, South Africa. AfroCentric Investment Corporation Limited is a subsidiary of Sanlam Life Insurance Limited.

Company Details

  • SectorHealthcare
  • IndustryMedical Care Facilities
  • CEOMr. Gerald N. Van Wyk
  • Employees0
  • Headquarters37 Conrad Road, Roodepoort, South Africa, 1709, South Africa
  • Websitehttps://www.afrocentric.za.com

Leadership

  • Mr. Gerald N. Van WykGroup CEO & Director
  • Mr. K. Thato MoloeleCFO & Executive Director
  • Mr. Monwabisi KulaChief Risk Officer
  • Mr. Satish AntonyChief Analytics & Strategy Officer
  • Mr. Jeremy YattChief Growth Officer
  • Ms. Lebohang MpumlwanaGroup Company Secretary · b. 1985

Financials

Income Statement

Currency: ZAR2007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue--519.87M1.26B1.35B1.45B1.77B1.96B2.10B3.15B3.78B4.21B5.30B6.44B8.07B8.72B8.76B8.79B8.50B7.30B
Growth (%)---+143.03%+6.95%+7.18%+22.24%+10.62%+7.15%+50.03%+20.22%+11.31%+25.73%+21.60%+25.36%+8.03%+0.43%+0.39%-3.32%-14.11%
Cost of Revenue------121.00M116.54M100.04M694.97M937.78M987.24M1.40B1.51B1.97B2.27B4.23B5.14B3.56B2.52B
Gross Profit--519.87M1.26B1.35B1.45B1.65B1.84B2.00B2.45B2.85B3.23B3.90B4.93B3.55B6.45B4.78B3.65B4.94B4.78B
Gross Margin--100.00%100.00%100.00%100.00%93.17%94.05%95.23%77.92%75.22%76.57%73.54%76.61%43.97%73.93%54.61%41.55%58.10%65.46%
Operating Expense--470.59M1.15B1.10B1.19B1.39B1.49B1.72B2.16B2.48B2.60B3.43B4.27B2.78B5.72B1.14B3.10B4.26B4.62B
Operating Income-6.68M-1.37M49.28M110.00M255.09M259.30M258.62M356.36M279.36M296.15M366.66M623.09M464.29M662.64M775.15M733.58M3.64B550.37M675.07M159.18M
Operating Margin--9.48%8.71%18.88%17.90%14.61%18.20%13.31%9.41%9.69%14.79%8.77%10.29%9.60%8.41%41.57%6.26%7.94%2.18%
EBITDA6.70M-1.37M77.40M86.31M223.11M299.18M383.75M343.02M354.78M382.96M484.66M657.39M811.53M983.71M1.09B1.13B864.71M651.84M577.75M-63.78M
EBITDA Margin--14.89%6.83%16.51%20.66%21.68%17.52%16.91%12.16%12.81%15.61%15.32%15.27%13.48%12.98%9.87%7.41%6.79%-0.87%
Net Income4.67M10.81M34.70M-7.41M117.25M164.51M184.11M170.66M154.03M165.25M117.67M256.61M269.88M303.57M302.03M312.80M183.52M55.38M-28.80M-1.27B
Net Income Margin--6.67%-0.59%8.68%11.36%10.40%8.71%7.34%5.25%3.11%6.09%5.10%4.71%3.74%3.59%2.09%0.63%-0.34%-17.45%
R&D--------14.82M51.73M48.91M30.11M35.30M68.85M86.82M111.78M119.21M114.56M--
R&D as % of Total Revenue--------0.71%1.64%1.29%0.71%0.67%1.07%1.08%1.28%1.36%1.30%--
Interest Expense7.83M11.35M8.10M22.60M15.66M3.37M15.97M754.00K10.00M3.00M45.91M1.86M52.01M71.73M57.09M75.83M94.19M96.23M81.05M75.50M
Interest Expense % of Total Revenue--1.56%1.79%1.16%0.23%0.90%0.04%0.48%0.10%1.21%0.04%0.98%1.11%0.71%0.87%1.08%1.09%0.95%1.03%

Balance Sheet

Currency: ZAR2007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets105.52M222.70M1.74B1.18B1.24B1.36B1.53B1.56B1.59B3.04B3.07B3.13B4.45B4.55B5.11B5.44B5.56B5.41B5.16B4.18B
Total Liabilities2.40M10.36M1.09B533.60M495.35M449.86M475.58M437.11M418.53M1.48B689.83M510.17M1.57B1.43B1.86B1.99B2.06B2.01B1.88B2.24B
Total Equity103.13M212.35M622.02M620.29M726.85M882.82M1.00B1.07B1.10B1.05B1.79B1.94B2.10B2.22B2.33B2.45B3.44B3.37B3.25B1.90B
Cash105.52M10.42M65.55M122.52M180.01M241.91M359.21M388.45M333.05M372.07M361.74M212.92M265.30M177.68M198.94M138.59M189.76M330.26M347.80M607.36M
Total Debt-5.11M287.63M202.19M228.74M220.87M220.97M163.73M81.17M21.29M18.98M15.91M814.22M664.59M995.90M849.83M996.34M805.49M790.80M743.69M
Net Debt-105.52M-5.31M222.07M79.66M48.72M-21.05M-138.25M-224.72M-251.88M-350.78M-342.76M-197.00M548.92M486.91M796.96M711.24M806.58M475.23M443.00M136.33M

Cash Flow

Currency: ZAR2007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Operating Cash Flow-802.00K-8.11M47.22M115.83M103.99M116.24M227.08M141.94M177.40M191.73M205.19M290.52M306.77M501.71M385.26M527.02M381.69M814.47M548.07M684.90M
Investing Cash Flow7.84M-92.10M-165.67M-68.55M-88.87M-55.35M-114.46M-62.94M-137.06M-645.47M-212.94M-298.08M-679.40M-431.75M-658.21M-382.97M-287.48M-382.77M-357.07M-221.76M
Financing Cash Flow98.22M-179.22M-8.78M43.05M8.31M3.78M-49.85M-96.60M487.93M-176.75M-138.60M428.91M-157.19M298.59M-208.27M-151.95M-179.35M-40.38M-70.52M
Capital Expenditure0046.70M91.38M77.89M089.20M110.72M235.63M278.31M249.62M524.64M340.55M421.18M493.83M303.69M258.42M262.15M253.21M219.34M
Free Cash Flow-802.00K-8.11M522.00K24.46M26.11M116.24M137.88M31.22M-58.23M-86.57M-44.43M-234.12M-33.79M80.53M-108.56M223.33M123.27M433.22M294.86M465.56M
Dividends Paid------33.22M70.18M131.00M121.96M144.14M166.31M186.32M239.14M327.71M293.92M163.83M119.10M4.55M-
FCF to OCF100.00%100.00%1.11%21.11%25.11%100.00%60.72%22.00%-32.83%-45.15%-21.65%-80.59%-11.01%16.05%-28.18%42.38%32.30%53.19%53.80%67.97%
Dividend Paid to FCF------24.09%224.76%-224.96%-140.88%-324.39%-71.04%-551.46%296.96%-301.86%131.61%132.90%27.49%1.54%-

Key Statistics & Ratios

Market Cap605.94M
Enterprise Value605.30M
Trailing P/E0.00
Forward P/E8.37
PEG Ratio57.50
Price / Sales0.08
Price / Book0.29
EPS-0.81
Book Value2.32
Revenue (TTM)7.26B
Gross Profit (TTM)3.52B
EBITDA2.13B
Profit Margin-17.98%
Operating Margin26.93%
Return on Equity-22.86%
Return on Assets25.86%
Shares Outstanding818.83M
Shares Float27.46M
Beta0.21
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20222×
17.00Nov 9, 202217.00May 11, 2022
20212×
17.00Nov 10, 202117.00May 12, 2021
20202×
17.00Nov 11, 202017.00May 6, 2020
20192×
17.00Oct 30, 201917.00May 7, 2019
20182×
16.00Nov 7, 201816.00May 9, 2018
20172×
14.00Nov 8, 201714.00May 10, 2017
20162×
12.00Nov 9, 201612.00May 9, 2016
20152×
10.00Oct 19, 201510.00May 11, 2015
20142×
18.00Nov 24, 20141.36Feb 10, 2014
20121×
10.50Dec 10, 2012
20112×
9.00Nov 21, 20117.50Jan 10, 2011
20051×
33.37Dec 9, 2005

Stock Splits

  • Jul 17, 200649211:9022